USANA Health Sciences, Inc. updated earnings guidance for the year 2023. Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.56 USD | -2.43% | +1.31% | -9.40% |
May. 07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
May. 01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.40% | 948M | |
+15.92% | 8.47B | |
+3.37% | 7.6B | |
+1.49% | 6.26B | |
-5.33% | 3.78B | |
-7.57% | 3.73B | |
-2.94% | 1.35B | |
-26.08% | 1.12B | |
+14.95% | 998M | |
-17.96% | 808M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023